Communiqués Alexion Pharmaceuticals, Inc. Xetra

Actions

AXP

US0153511094

Temps Différé Xetra Autres places de cotation 17:35:30 20/07/2021			Varia. 5j.	Varia. 1 janv.
153,9 ^EUR	+0,72%		-.--%	-.--%

21/05	Astrazeneca vise une hausse de 75% de son chiffre d'affaires	AW
01/04	VOYDEYA d'Alexion Pharmaceuticals, Inc. est approuvé aux États-Unis comme traitement d'appoint au ravulizumab ou à l'éculizumab pour le traitement de l'hémolyse extravasculaire chez les adultes atteints de la maladie rare qu'est la PNH.	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023	17/05/23	AQ
Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas	08/05/23	AQ
AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022	01/12/22	AQ
Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio Therapeutics	17/11/22	AQ
AstraZeneca expands global footprint in rare disease with availability of first Alexion rare disease therapy for patients in China	11/11/22	AQ
Alexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine	04/10/22	AQ
Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type 1	28/09/22	AQ
Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type1	28/09/22	AQ
Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gravis	26/09/22	AQ
Danicopan (ALXN2040) add-on to Ultomiris or Soliris met primary endpoint in ALPHA Phase III trial for patients with paroxysmal	16/09/22	AQ
Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis	26/08/22	AQ
Astrazeneca - Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis	25/08/22	AQ
Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis	25/07/22	AQ
AstraZeneca demonstrates pipeline and portfolio strength across malignant and rare haematological diseases at EHA 2022	10/06/22	AQ
Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder	05/05/22	AQ
Ultomiris approved in the US for adults with generalised myasthenia gravis	28/04/22	AQ
Breaking PMPRB News: Another Win For Patients And The Innovative Pharmaceutical Industry	26/04/22	AQ
PMPRB Update: PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing	12/04/22	AQ
SCC Leave Denied In Alexion Pharmaceuticals Inc v Canada (Attorney General)	31/03/22	AQ
PMPRB Update: Supreme Court Refuses To Hear Appeal From Decision Restricting Canada's Patented Medicine Pricing Review Board's Drug Price Mandate	29/03/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Alexion Pharmaceuticals, Inc. Xetra

Actions

AXP

US0153511094

Communiqués

Filtres